Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial.
Imafuku S, Okubo Y, Tada Y, Ohtsuki M, Colston E, Napoli A, Shao Y, Banerjee S, Morita A.
J Dermatol. 2024 Mar;51(3):365-379. doi: 10.1111/1346-8138.17074. Epub 2024 Jan 24.
PMID:38268101
Autoinflammatory pustular neutrophilic diseases.
Naik HB, Cowen EW.
Dermatol Clin. 2013 Jul;31(3):405-25. doi: 10.1016/j.det.2013.04.001. Epub 2013 Jun 2.
PMID:23827244
Intradermal injection of Cutibacterium acnes and staphylococcus: A pustular acne-like murine model.
Zhou N, Sun Y, Ren X, Wang Y, Gao X, Li L, Ma Y, Hao Y, Wang Y.